Artwork

Content provided by Colabra. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Colabra or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Overcoming CAR-T Cell Bottlenecks - Dr. Andy Scharenberg

46:41
 
Share
 

Manage episode 416331736 series 3312469
Content provided by Colabra. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Colabra or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Immunotherapy is weaponizing the body's immune system against cancer or other disease. One of the most promising approaches is CAR-T cell therapy, yet as this technology has been implemented, it's limitations have been identified. Dr. Andy Scharenberg described the current drawbacks of CAR-T cells and how his company, Umoja, is re-engineering CAR-T cells in vivo to create more effective therapies, including approaches that can address solid tumors. Co-hosted by Donald Coon.

www.umoja-biopharma.com

  continue reading

432 episodes

Artwork
iconShare
 
Manage episode 416331736 series 3312469
Content provided by Colabra. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Colabra or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Immunotherapy is weaponizing the body's immune system against cancer or other disease. One of the most promising approaches is CAR-T cell therapy, yet as this technology has been implemented, it's limitations have been identified. Dr. Andy Scharenberg described the current drawbacks of CAR-T cells and how his company, Umoja, is re-engineering CAR-T cells in vivo to create more effective therapies, including approaches that can address solid tumors. Co-hosted by Donald Coon.

www.umoja-biopharma.com

  continue reading

432 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide